This study evaluates the clinical efficacy of ambroxol hydrochloride in treating infantile secretory otitis media (SOM). Ninety-two infants diagnosed with SOM were randomly divided into an experimental group receiving conventional treatment plus ambroxol hydrochloride, and a control group receiving routine care alone. Treatment effectiveness, inflammatory markers (SIL-2R and IL-8), pure tone threshold air-bone gap, tympanic pressure, and adverse reactions were compared. The experimental group demonstrated a significantly higher treatment effectiveness rate (P<0.05), increased SIL-2R and IL-8 levels (P<0.05), reduced air-bone gap (P<0.05), improved tympanic pressure (P<0.05), and lower incidence of adverse reactions (P<0.05) compared to controls. These results indicate that ambroxol hydrochloride enhances clinical outcomes and safety in infant SOM treatment, supporting its valuable application in clinical nursing.
liwen et al. (Tue,) studied this question.